Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pola-ZR2P in Previously Untreated DLBCL
Sponsor: Navy General Hospital, Beijing
Summary
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
Official title: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Key Details
Gender
All
Age Range
14 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-09-24
Completion Date
2030-12
Last Updated
2025-08-19
Healthy Volunteers
No
Conditions
Interventions
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
Locations (1)
Navy General Hospital
Beijing, Beijing Municipality, China